Investor Overview

Neovasc is a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina. The company currently has two devices. The Reducer is CE-marked in the European Union and under FDA review for the treatment of refractory angina. The Reducer provides relief of angina symptoms by altering blood flow in the heart’s circulatory system, thereby increasing the perfusion of oxygenated blood to ischemic areas of the heart muscle. Tiara is a self-expanding mitral bioprosthesis for treatment of mitral valve regurgitation (“MR”) by replacing the diseased valve.

Conventional surgical treatments are only appropriate for about half of MR patients, who number an estimated four million in the U.S. with a similar number of patients in Europe. Tiara is implanted using a minimally invasive, transcatheter approach which avoids open-heart surgery or use of a cardiac bypass machine. The Tiara valve is not commercially available and is currently being evaluated in two ongoing clinical trials in the US, CA, Europe and Israel.


detail >


detail >

Latest News

Neovasc Announces New Appointments in Regulatory and Clinical Leadership

> read full release

Archive >

Presentations and Events

Neovasc Strategy Presentation

.pptx format > .pdf format >

Neovasc Q1 2021 Earnings Call

Thursday, May 6th, 2021, 4:30 p.m. ET

webcast >
recent presentations and events >

2021 Annual General Meeting

Thursday June 3, 2021 11:00am ET




documents >

Neovasc Q1 2021 Earnings Call

Thursday, May 6th, 2021, 4:30p.m. ET




audio webcast here >

Financial Report Archives

2021 Financial Reports

News Release Archives

2021 News Releases

Share Information

Grant Thornton LLP, Vancouver, BC

Legal Counsel
Blakes LLP, Vancouver, BC

Transfer Agent
Computershare, Vancouver, BC

Investor Relations
Chris Clark, Chief Financial Officer

To receive news updates via email;

register now